The Real Cost of GLP-1 Medications in 2026 (With and Without Insurance)

GLP-1 medications are among the most clinically effective weight management and diabetes treatments ever developed — and among the most expensive medications in American pharmacies. A single month's supply of Wegovy or Zepbound lists at over $1,000. For many patients, the biggest barrier to treatment isn't side effects or injections — it's the monthly bill.

This guide breaks down the actual 2026 pricing landscape: list prices, what insurance typically pays, manufacturer savings programs, GoodRx, and alternatives including compounded versions. Numbers here are as current as possible, but drug pricing changes frequently — always verify at the pharmacy counter and use our cost estimator for real-time comparisons.

List Prices in 2026

"List price" is the sticker price before any insurance adjustment, discount card, or coupon is applied. Very few patients pay list price, but it establishes the ceiling.

Medication	Active Ingredient	Indication	Approx. List Price/Month
Ozempic 0.5 mg	Semaglutide	Type 2 diabetes	~$935
Ozempic 1 mg	Semaglutide	Type 2 diabetes	~$935
Ozempic 2 mg	Semaglutide	Type 2 diabetes	~$990
Wegovy 2.4 mg	Semaglutide	Obesity/CVD risk	~$1,349
Mounjaro 5–15 mg	Tirzepatide	Type 2 diabetes	~$1,069
Zepbound 5–15 mg	Tirzepatide	Obesity/CVD risk	~$1,059
Saxenda (3 mg daily)	Liraglutide	Obesity	~$1,349

Prices based on manufacturer list prices and GoodRx data as of May 2026. Prices vary by pharmacy and region.

The relative pricing parity between semaglutide and tirzepatide products is notable — tirzepatide (Mounjaro/Zepbound) is slightly less expensive by list price despite producing larger average weight loss, reflecting competitive market dynamics since Zepbound's 2023 launch.

What Insurance Actually Pays

Coverage varies enormously based on insurance type, plan design, diagnosis, and formulary tier.

Commercial Insurance (Employer-Sponsored or Individual Market)

For diabetes (Ozempic, Mounjaro): Most commercial plans cover Ozempic and Mounjaro for type 2 diabetes, typically on Tier 3 or Tier 4 (specialty tier). Patient cost-sharing ranges from $50–$200/month with a standard commercial plan, or up to $400+/month on high-deductible plans before meeting the deductible.

For obesity (Wegovy, Zepbound): Coverage is inconsistent. A 2023 survey by the Obesity Medicine Association found that fewer than 40% of commercially insured Americans have obesity medication coverage through their employer plan. Coverage has been expanding as employer cost-benefit analyses show ROI — particularly large self-insured employers — but exclusions remain common.

Key check: Call your insurance's member services and ask specifically: "Is Wegovy [or Zepbound] covered on my formulary for obesity with a BMI of [your BMI]? What is my cost-sharing?" Don't rely on general coverage lists.

Medicare

• Ozempic and Mounjaro: Covered under Medicare Part D for type 2 diabetes
• Wegovy and Zepbound: As of 2026, Medicare Part D covers Wegovy and Zepbound for patients who have established cardiovascular disease (following the 2024 FDA indication expansions based on the SELECT trial). Coverage for obesity alone, without CVD, remains limited under Medicare Part D as a result of the exclusion of obesity drugs in the Medicare Modernization Act of 2003. This legislative exclusion has been the target of the Treat and Reduce Obesity Act, which as of this publication has not been passed.

Medicaid

Coverage varies by state. Some state Medicaid programs cover GLP-1 medications for diabetes; coverage for obesity is more variable. Check your state's Medicaid formulary or contact your state's Medicaid office directly.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly operate savings programs that can dramatically reduce out-of-pocket costs for commercially insured patients.

Novo Nordisk (Ozempic, Wegovy)

Ozempic Savings Card: - Eligible commercially insured patients may pay as little as $25/month for up to 24 months - Not available to Medicare, Medicaid, or uninsured patients - Enrollment at ozempic.com/savings

Wegovy Savings Program: - Eligible commercially insured patients may pay as little as $0/month for the first month, then varying rates based on insurance - Program enrollment and eligibility at wegovy.com - Also not available to federal program beneficiaries (Medicare/Medicaid)

Eli Lilly (Mounjaro, Zepbound)

Mounjaro Savings Card: - Eligible commercially insured patients may pay as little as $25/month - Enrollment at mounjaro.com

Zepbound Savings Program: - Eligible commercially insured patients may pay as little as $25/month - Lilly also offers LillyDirect, a direct-to-patient self-pay program: - Doses 2.5 mg and 5 mg: approximately $349/month - Doses 7.5 mg, 10 mg, 12.5 mg: approximately $499/month - Dose 15 mg: approximately $549/month - LillyDirect self-pay applies regardless of insurance status — it's Lilly's response to access and affordability concerns

GoodRx and Discount Cards

GoodRx is a free service that negotiates discounted prescription prices with pharmacies. For GLP-1 medications, GoodRx discounts are typically modest compared to manufacturer savings programs — but they are available to uninsured patients and those on Medicare, who cannot use manufacturer savings cards.

Typical GoodRx prices (May 2026, varies by pharmacy): - Ozempic 1 mg: ~$850–$950/month at major chains - Wegovy 2.4 mg: ~$1,100–$1,300/month - Mounjaro 10 mg: ~$950–$1,050/month - Zepbound 10 mg: ~$900–$1,000/month

GoodRx is most useful for lower-dose tiers and for comparison shopping between pharmacies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently carry brand-name GLP-1 injectables but is worth monitoring as the market evolves.

Compounded Semaglutide and Tirzepatide

During shortage periods (2022–2024), the FDA permitted compounding pharmacies to produce copies of semaglutide and tirzepatide. Compounded versions are significantly cheaper:

• Compounded semaglutide: ~$150–$350/month (telehealth platforms including Hims & Hers, Ro, Mochi Health, Calibrate)
• Compounded tirzepatide: ~$200–$400/month

However, the regulatory situation is complex and evolving:

These medications are investigational or compounded and not FDA-approved for weight loss. Information here is educational only — not a recommendation. Do not source medications from unverified suppliers.

The FDA's shortage designation — which authorized compounding — was lifted for tirzepatide in early 2025 and has been contested for semaglutide. As of May 2026, the legality of commercially compounded GLP-1s is in legal flux, with multiple lawsuits between compounders and the FDA. Before pursuing a compounded option, verify current FDA status at fda.gov/drugs/drug-safety-and-availability/drug-shortages and confirm your compounding pharmacy holds proper accreditation (503A or 503B facility designation). See our dedicated article on compounded GLP-1 safety and options.

Prior Authorization: The Hidden Time Cost

Even when insurance covers GLP-1 medications, prior authorization (PA) is nearly universal. PA requires your prescriber to submit documentation demonstrating medical necessity before the insurer will pay.

For obesity medications, typical PA requirements include: - BMI ≥30 (or ≥27 with documented comorbidity) - Documentation of prior weight loss attempts (diet programs, other medications) - Absence of contraindications - Sometimes: specialist referral or letter of medical necessity

PA approvals typically take 3–14 business days. Denials are common — but appeals succeed at meaningful rates. If denied, ask your prescriber for a peer-to-peer review (where your doctor speaks directly with the insurance medical director) — this is one of the most effective appeals strategies.

What Patients Actually Pay: Real-World Cost Distribution

A 2024 analysis published in JAMA Health Forum examined actual out-of-pocket costs for patients prescribed GLP-1 medications for obesity:

• Commercially insured with coverage: median ~$70/month after savings programs
• Commercially insured without coverage: median ~$660/month
• Medicare beneficiaries: median ~$500/month (before 2024 CVD indication expansion)
• Uninsured: median ~$1,050/month (list price minus any discount card savings)

These numbers explain why medication discontinuation rates are high among uninsured and underinsured patients — adherence drops sharply when out-of-pocket costs exceed $200/month.

Strategies to Reduce Your Cost

1. Confirm insurance coverage before starting. Call your insurer with your specific diagnosis code (E11.x for T2D, E66.x for obesity, Z68.x for BMI documentation).
2. Enroll in manufacturer savings programs if you're commercially insured — these are legitimate, legal, and can reduce costs to $0–$25/month.
3. If on Medicare with CVD: Verify Wegovy/Zepbound coverage under your Part D plan — the cardiovascular indication may trigger coverage.
4. If uninsured: Consider the LillyDirect self-pay program for Zepbound (starting ~$349/month), which is manufacturer-direct and uses the authentic branded product.
5. Use GoodRx for comparison. Even if you have insurance, GoodRx is occasionally cheaper than your insurance copay for certain pharmacies.
6. If appealed and denied: Contact the Obesity Action Coalition or your state insurance commissioner for appeals assistance.
7. Ask about dose flexibility: Some patients do well on doses below the maximum. At lower doses, cost is the same (pens are fixed), but maintaining a lower effective dose may be acceptable long-term.

Use our cost estimator to model your specific insurance and income scenario.

Sources

1. Novo Nordisk. "Wegovy Savings Program." https://www.wegovy.com/coverage-and-cost/savings-program.html
2. Eli Lilly. "LillyDirect Zepbound Self-Pay Program." https://www.zepbound.lilly.com/savings
3. GoodRx. "GLP-1 Medication Price Comparison." https://www.goodrx.com/conditions/type-2-diabetes/glp-1-agonists
4. JAMA Health Forum. "Out-of-Pocket Costs for GLP-1 Medications for Obesity." 2024. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2818033
5. KFF. "Claims Denials and Appeals in ACA Marketplace Plans." https://www.kff.org/private-insurance/issue-brief/claims-denials-and-appeals-in-aca-marketplace-plans/
6. FDA Drug Shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
7. Obesity Medicine Association. "Coverage for Anti-Obesity Medications." https://obesitymedicine.org/weight-loss-medications/